HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy

Article excerpt

The Department of Health and Human Services confirmed Thursday that Americans exposed to Ebola during the current Central African outbreak will have access to MBP-134, an antibody treatment made by San Diego-based Mapp Biopharmaceuticals. The drug has shown promise in animal testing but has never been tested in human clinical trials to prove it actually works in people. The decision allows the experimental therapy to reach high-risk patients while the company races to develop a treatment for a virus that has no proven cure.